0000899243-19-023452.txt : 20190912 0000899243-19-023452.hdr.sgml : 20190912 20190912170120 ACCESSION NUMBER: 0000899243-19-023452 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190912 FILED AS OF DATE: 20190912 DATE AS OF CHANGE: 20190912 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Riebe Michael T CENTRAL INDEX KEY: 0001787242 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39041 FILM NUMBER: 191090896 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BOULEVARD, SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001692830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813039831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BOULEVARD STREET 2: SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 64080 BUSINESS PHONE: 415-505-0809 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BOULEVARD STREET 2: SUITE 221 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 64080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-09-12 0 0001692830 Satsuma Pharmaceuticals, Inc. STSA 0001787242 Riebe Michael T C/O SATSUMA PHARMACEUTICALS, INC. 400 OYSTER POINT BOULEVARD, SUITE 221 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Stock Option (Right to Buy) 0.90 2027-10-30 Common Stock 12765 D Stock Option (Right to Buy) 1.04 2028-05-01 Common Stock 12765 D Stock Option (Right to Buy) 4.56 2029-05-16 Common Stock 14893 D Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vested and became exercisable in successive, equal monthly installments over two years measured from November 1, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 15, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Thomas P. O'Neil as Attorney in Fact for Michael T, Riebe, Ph.D.. 2019-09-12 EX-24 2 attachment1.htm EX-24 DOCUMENT



                               POWER OF ATTORNEY

    KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and
appoints each of (i) the Chief Executive Officer of Satsuma Pharmaceuticals,
Inc., a Delaware corporation (the "Company"), who is currently John A. Kollins,
(ii) the Company's Chief Financial Officer, who is currently Thomas P. O'Neil,
and (iii) the Company's General Counsel and their respective successors, signing
singly, with full power of substitution, as the undersigned's true and lawful
attorney-in-fact to:

    (1)	execute for and on behalf of the undersigned, in the undersigned's
        capacity as an officer and/or director of the Company, Forms 3, 4 and 5
        (including amendments thereto) in accordance with Section 16(a) of the
        Securities Exchange Act of 1934 and the rules and regulations thereunder
        and a Form ID, Uniform Application for Access Codes to File on EDGAR;

    (2)	do and perform any and all acts for and on behalf of the undersigned
        which may be necessary or desirable to complete and execute any such
        Forms 3, 4 or 5 or Form ID and timely file such forms (including
        amendments thereto) and application with the United States Securities
        and Exchange Commission and any stock exchange or similar authority; and

    (3)	take any other action of any type whatsoever in connection with the
        foregoing which, in the opinion of such attorney-in- fact, may be of
        benefit to, in the best interest of, or legally required by, the
        undersigned, it being understood that the documents executed by such
        attorney- in-fact on behalf of the undersigned pursuant to this Power of
        Attorney shall be in such form and shall contain such terms and
        conditions as such attorney-in- fact may approve in such attorney-in-
        fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

    The undersigned agrees that each such attorney-in-fact herein may rely
entirely on information furnished orally or in writing by the undersigned to
such attorney-in-fact.  The undersigned also agrees to indemnify and hold
harmless the Company and each such attorney-in-fact against any losses, claims,
damages or liabilities (or actions in these respects) that arise out of or are
based upon any untrue statements or omission of necessary facts in the
information provided by the undersigned to such attorney-in fact for purposes of
executing, acknowledging, delivering or filing Forms 3, 4 or 5 (including
amendments thereto) or Form ID and agrees to reimburse the Company and such
attorney-in-fact for any legal or other expenses reasonably incurred in
connection with investigating or defending against any such loss, claim, damage,
liability or action.

    This Power of Attorney supersedes any power of attorney previously executed
by the undersigned regarding the purposes outlined in the first paragraph hereof
("Prior Powers of Attorney"), and the authority of the attorneys-in-fact named
in any Prior Powers of Attorney is hereby revoked.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier (a) revoked by the undersigned in a signed writing delivered to
the foregoing attorneys-in-fact or (b) superseded by a new power of attorney
regarding the purposes outlined in the first paragraph hereof dated as of a
later date.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 28th day of August, 2019.


                               /s/ Michael T. Riebe
                              ------------------------------------
                              MICHAEL T. RIEBE, PH.D.